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Administration of soy may stimulate increase levels of glucagon-like 
peptide 1 (GLP-1). Giving soy supplements to people with diabetes can 
reduce blood glucose levels significantly. However, no studies have shown 
this reduction effect of glucose level back to normal levels. This study aimed 
to determine the blood insulin and glucose levels after supplementation of 
soybean-based food supplements in patients with type 2 diabetes mellitus 
(T2DM) and the sequencee of DNA of GLP-1 gene. This experimental study 
was a randomized, treatment controlled; open clinical trial study conducted 
by comparing the group treated with soybean supplement products 
containing 18g protein and the group of placebo. Seventy-six, subjects with 
T2DM were recruited from Muhammadiyah Gamping Hospital and 
PERSADIA Gymnastics, Yogyakarta, based on the inclusion and exclusion 
criteria. All subyects were grouped randomly into the supplement group and 
placebo group. Blood sampling was drawn at 8h fasting, 2h after 
administration of supplement and 2h after administration of 75g glucose. 
The determination of blood insulin and glucose level and DNA sequencing 
were performed. Blood insulin level 2h after supplement administration 
(mean±SEM) increased 5.3±0.8µIU/mL (n=37) while placebo decreased 
0.9±0.4µIU/mL (n=39) which was significantly different (p<0.05). In both 
groups blood glucose levels incresed as much as 130.0±11.5mg/dl (n=37) 
and 146.7±8.2mg/dL (n=39) (p>0.05), for the supplement treated and 
placebo groups, respectively. DNA sequencing shows a nucleotide variation 
of GLP-1 (37 amino acid) in Javanese T2DM. It may be concluded that 
administration of soybean-based supplements containing 18g protein 
increased blood insulin levels and decreased blood glucose levels. 
Keywords: soybean supplements, insulin, blood glucose, type 2 diabetes 
mellitus, GLP-1 gene 
 
INTRODUCTION  
The International Diabetes Federation 
(2015) estimates that people with diabetes 
mellitus (DM) in the world reached 415 million in 
2015 and will increase to 642 million by 2040. Ten 
countries with the largest population of DM 
sufferers in the world are India, China, America, 
Indonesia, Japan, Pakistan, Russia, Brazil, Italy and 
Bangladesh (Khardori, 2016). DM is a risk factor for 
cardiovascular disease. It may be controlled by 
treatment with anti-diabetic drugs and dietary 
restrictions (Balitbangkes, 2013). DM management 
is conducted by the efforts of non-pharmacologic 
and pharmacologic treatment administration.  
Non-pharmacological interventions involve 
applying healthy lifestyles and pharmacological 
interventions by administering drugs orally and/or 
injections (PERKENI, 2015). Encouragement of 
herbal medicine (jamu) research based on health 
services promoted by Indonesian government 
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since 2010 has increased the use of herbal 
medicine for patient services by the medical 
profession. This approach requires  support of 
scientific studies on efficacy and safety the herbal 
medicines (Delima et al., 2012; Herman et al., 
2013). 
Two hours after administration of soy 
supplements to people with T2DM showed 
postprandial glucose levels were significantly 
lower compared to controls (p<0.05) (Chang et al., 
2008; Kwak et al., 2010). Soy milk can reduce blood 
glucose levels in people with diabetes mellitus 
(Cahyono, 2011). Giving soy milk for 14 days 
decreases fasting blood glucose levels in 
prediabetes women (Sinaga & Wirawanni, 2013). 
Soybean supplements can reduce blood glucose 
levels in diabetic mice and increase white blood 
cells compared to the normal saline control group 
(Sada et al., 2013). Chang et al. (2013) reviewed 
hundreds of papers that discussed the structure, 
activity, and mechanisms of the actions of various 
plant chemical compounds for the treatment of 
type 2 diabetes mellitus (T2DM). Among plants that 
have the effect of improving the condition of 
hyperglycemia in the models and in patients those 
with T2DM are soybean plants. Giving soy flour 
fortified bread did not have a significant effect on 
the metabolic profile including fasting glucose 
levels, cholesterol, triglycerides, LDL cholesterol, 
and HDL cholesterol compared to the usual diet in 
diabetic patients (Moghaddam et al., 2014). 
Administration of 280mL soy milk per day for 14 
days can reduce blood sugar levels of people with 
type 2 diabetes mellitus compared to the placebo 
control group (Baequny et al., 2015). The habit of 
consuming phytoestrogens, especially in the form 
of whole food sources such as soybeans and 
flaxseed, can be considered as a healthy diet for 
prevention and management of type 2 DM (Talaei, 
2015). Isoflavone intake is associated with a lower 
risk of T2DM in US people who usually consume 
small to moderate amounts of soy foods (Ding et al., 
2016). Consumption of soy and cow's milk induces 
a decrease in similar glycemic responses (Sun et al., 
2016). Supplementation of soy protein more than 6 
months significantly reduces Fasting Plasma 
Glucose, LDL-Cholesterol in T2DM and metabolic 
syndrome (Zhang et al., 2016). High intake of 
soybeans and isoflavones can reduce the risk of 
lower type 2 diabetes in Vietnamese adults 
(Nguyen et al., 2017). Administration of 15g of soy 
protein with 66mg of isoflavones improved 
significant glycemic control compared to 15g of soy 
protein without isoflavones (Sathyapalan et al., 
2017). The combination of soybean and ginger 
rhizome extract reduced blood glucose levels 
better than single soybean seed extract in diabetic 
mice (Purnomo, 2018). Soy products may be 
associated with a lower risk of T2DM but requiring 
further studies that focuses on the dose-response 
and mechanism of action (Li et al., 2018).  
Treatment of soybeans containing 50g of 
protein increased GLP-1 levels by approximately 
6pg/mL at 30min and remained at almost the             
same level for up to 2-3h after administration with 
a significant difference compared to glucose in 
overweight (Bowen et al., 2006). The administration 
of macronutrients containing soybeans increase 
levels of glucagon-like peptide 1 (GLP-1) (Douglas 
et al., 2015). (GLP-1) is released by intestinal L-cells 
after stimulating nutrients and regulating glucose 
levels by stimulating insulin secretion (Janus et al., 
2019). Genistein stimulate secretion of insulin 
through cAMP-dependent protein kinase pathway 
(Liu et al., 2006). Amino acids play an important 
role in stimulating GLP-1 (Mansour et al., 2013). 
Bioactive of soy hydrolyzates stimulate an increase 
in GLP-1 (Tulk et al., 2014). Genistein activates 
AMPK so that it can reduce insulin resistance 
(Chang et al., 2013). AMPK alters the transcription 
and secretion of GLP-1 in intestinal secretin tumor 
cell line (STC-1) culture (Jiang et al., 2016). Soy milk 
increases incretin levels (GLP-1 and GIP) which 
have an effect on reducing blood glucose levels 
(Sun et al., 2016). 
Although the effect of giving soybeans in 
reducing blood glucose levels in people with T2DM 
has been demonstrated an adequate clinical 
evidence is needed for its therapeutic use in 
medicinal treatments. Therefore, the study was 
conducted to determine how much insulin and 
blood glucose levels is altered in T2DM by 
administration of soy-based supplements. 
 
MATERIALS AND METHODS 
This experimental study was performed by 
randomized, controlled treatment using an open 
clinical trial design comparing treatment groups 
administered soybean supplement products 
containing 18g of protein to control groups given 
placebo (water) in patients with T2DM. The 
subjects of the study were 76 people with T2DM 
recruited from The Hospital of PKU 
Muhammadiyah Gamping, Yogyakarta and the 
PERSADIA gymnastics group who fulfilled the 
inclusion and exclusion criteria. All subjects were 
willing to take part in the study by completing 
informed consent forms. The participants were 
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grouped randomly into 2 groups of supplement 
treatment and placebo control. Blood samples   
were drawn after 8h fasting and at 2h after 
administration of supplement product and or 
placebo. The third blood sampling were taken 2h 
after 75g glucose loading for measuring insulin and 
blood glucose. Levels and DNA sequencing of the 
the gene of GLP-1 (37 amino acids). 
 
The subjects were selected based on the 
inclussion and the exclussion criteria.  
Confounding variables include age, body 
mass index, lipid profile, and drug use were 
recorded. Age >45 years is a risk factor in the 
development of diabetes mellitus, obesity 
especially central obesity is closely related to the 
development of type 2 DM can be measured by 
body mass index. Obesity is also closely related to a 
person's lipid profile so it needs attention for not to 
interfering to the variables measured. The use of 
insulin or oral hypoglycemic agents that may 
interfere glucose level should be controlled. 
Therefore, the blood sampling and the 
administration of supplement were conducted at 
the time after the patients were fasting for at least 
10 hours or after the last dose of anti-hypoglycemic 
agent and or insulin. Efforts to minimize the 
influence of confounding factors were randomly 
allocated subjects into the study group or where 
possible avoiding these factors in the study. 
 
Instruments 
The equipment used in the study were 
Venopuncture and injection syringes used for 
taking blood sampling, EDTA tubes used for blood 
collection, cooler boxes, Elisa readers for insulin 
testing, and GENIUS clinical laboratory devices for 
blood glucose levels.  
 
Material 
A factory-made soy supplement product is 
obtained from market.  Thirty five (35) g of powder 
per serving mixed with 250mL of water with a 
shaker to obtain a protein content of 18g. To 
measure insulin levels an ELISA kit was used from 
CALBIOTECH® while the blood glucose level 
examinations used Glu Reagent Kit from Shenzhen 
Genius Electronic Co. Ltd. DNA template 
preparation of GLP-1 gene firstly was conducted by 
DNA isolation used Blood Genomic DNA Extraction 
Mini Kit With Proteinase from Favorgen Biotech 
Corp. Polymerase Chain Reaction (PCR) was 
performed used upstream oligonucleotide primer 
(forward) 5'CTCGCCTTCCTCGGCC3’ and 
downstream oligonucleotide primer (reverse) 
3'GAATAACATTGCCAAACGTCACG5' refers to 
coding region accession no NC_000002.12 
according to exon 4 glucagon preproprotein DNA, 
go taq® green master mix 2x1.25mL and nuclease 
free water.  
 
Treatment of the subjects: 
At the time of the study, subjects were 
available to the Clinical Laboratory of The Hospital 
of PKU Muhammadiyah, Gamping, Yogyakarta, for 
fasting blood collection at 06.00-07.00AM. 
Subsequently, all subjects were given either a glass 
of soybean supplement or a glass of water to the 
treatment group or to the placebo group, 
respectively. The suplement were given at 10h 
after the last dosing of antidabetic agent. Two 
hours after taking supplement or placebo, the 
second blood sampling was taken. The first and the 
second blood samples were analyzed for              
insulin and glucose level. After the second blood 
sampling, all the subjects took 2 pieces of white 
bread and drank a glass of sweet milk equivalent to 
75g of glucose. Two hours after eating white bread 
and drinking sweet milk blood samples were 
drawn again for the third time to measure the 2h 
postprandial blood glucose as glucose tolerance 
tests. Determination of insulin was performed              
by ELISA in the Biomedical Laboratory of  FM-PHN 
UGM. The GLP-1 (37 amino acid) gene sequencing 
was performed by 1st BASE DNA Sequencing  
Division of First Base Laboratories Sdn Bhd 
Malaysia. 
 
Polymerase Chain Reaction (PCR) for c-DNA of 
GLP1 
The PCR protocol was put in 30µL go               
taq® master mix, 2µL primer forward, 2µL primer 
reverse, 22µL nuclease-free water (NFW) and           
4µL DNA template into 2m PCR tubes  and then 
place the tubes in heat block of thermo cycler and 
proceed with the thermal cycler setting: 95ᵒC 5min 
for denaturation, 40 cycles (95ᵒC 1min, 57ᵒC 1min 
annealing temperature, 72ᵒC 1min), 70ᵒC 5min for 
extension and 4ᵒC indefinitely, finally the PCR 
result was observed by gel electrophoresis.  
PCR was conducted in biomedical laboratory 
of Faculty of Medicine - Public Health and Nursing 
(FM-PHN) UGM. Subsequently, The PCR results 
were sent to First Base Laboratories in Malaysia. 
Cycle sequencing, purification after cycle sequencing   
and   capillary   electrophoresis were conducted           
at the 1st BASE DNA Sequencing Division of              
First    Base     Laboratories    Sdn     Bhd    Malaysia.  
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Capillary electrophoresis results in the form of AB1 
files analyzed by BioEdit Sequence Alignment 
Editor for Windows. Sequencing of GLP-1 (37 
amino acid) gene used Applied Bio-systems 
automated DNA sequencing which consists of 5 
step includes DNA template preparation, cycle 
sequencing, purification after cycle sequencing, 
capillary electrophoresis. 
 
RESULTS AND DISCUSSION 
There are no significant differences were 
found between the placebo and the supplement 
groups in the term of variables which may affect 
blood glucose level and or insulin level such as age, 
sex, body weight and BMI, profile lipids, the length 
of diagnose of DM. Not any subjects involved  was  
categorized  as  obesity. Some of  the subjects are 
used to administer oral hypoglycemic agent or 
insulin or combination of the two, but at the time of 
having supplementation was assumed that the 
effect of all types of anti-diabetic agent were 
neglected (Table I).  
Fasting insulin levels in the supplement 
group were 11.8±2.5µIU/mL while the placebo 
group was 14.9±2.3µIU/mL, and the difference 
between them was statistically insignificant        
(Table II) Insulin levels in the treatment group after 
supplementation with soybean-based supplements 
increased to 17.0±2.8µIU/mL while the placebo 
group levels was still to be 14.0±2.3µIU/mL. The 
increase in insulin levels in the supplement group 
was 5.3±0.8µIU/mL and the decrease in the 
placebo group insulin level was 0.9±0.4µIU/mL. 
The changes of insulin level between the two 
groups was significant different  (p<0.05). 
The average fasting blood glucose                     
levels in both the supplementary and                       
placebo treatment groups were above the         
normal  value of fasting glucose levels according         
to    PERKENI,    2015     (>126mg/dL)     (Table   II).   
Table I. Characteristic of the subjects 
 
Variable Suplement Group Placebo Group Statistic significans 
 Sex ♂/♀ 18/19 18/21 P>0.05 
 Age (years) 56.6±1.3 57.6±1.4 P>0.05 
 Length of diagnose of 
DM (years) 
7.8±0.0 7.9±1.1 P>0.05 
 Body height (cm) 159±0.01 158±0.01 P>0.05 
 Body weight (kg) 64.6±2.3 64.56±1.8 P>0.05 
 BMI 25.0±0.6 25.1±0.6 P>0.05 
Blood presure 
 
Sistolik 
Diastolik 
140.3±2. 
77.2±1.5 
144.64±2.7 
80.4±2.2 
P>0.05 
P>0.05 
 Cholesterol level 219.8±11.8 19.24±10.1 P>0.05 
 HDL 46.5±1.7 47.7±1.8 P>0.05 
 LDL 126.1±7.1 113.4±7.5 P>0.05 
 Triglycerides 197.6±20.5 218.9±30.0 P>0.05 
Drugs used 
 
OHA 
OHA + insulin 
26 
11 
24 
15 
P>0.05 
P>0.05 
 
*Numerik data were tested by t-test Man Withney; *Categorical data were tested by Chi-square; OHA = oral 
hypoglycemic agent 
 
Table II. Blood Insulin Levels glucose 
 
Group 
Mean±SEM of Blood Insulin Level 
(µIU/mL) 
Mean±SEM of Blood Glucose Level 
(mg/dL) 
Supplement 
n=37 
Placebo-H2O 
n=39 
p-value 
Supplement 
n=37 
Placebo-H2O 
n=39 
p-value 
Fasting 11.8±2.5 14.9±2.3 >0.05 192.1±13.7 189.4±11.2 >0.05 
Post 
supplementation 
17.0±2.8 14.0±2.3 >0.05 221.0±14.9 181.1±11.6 <0.05 
Increase 5.3±0.8 (0.9±0.4) <0.05 351.0±19.8 327.5±14.3 >0.05 
 
SEM: Standard Error Mean 
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However, there is no significant differences of the            
blood glucose  level  between   the  two  groups 
(p>0.05). After supplementation of soybean 
supplement, blood glucose levels increased to 
221.0±14.9mg/dL (mean±SEM) while in the 
placebo group there was a decrease to 
181.1±11.6mg/dL (mean±SEM). The mean of            
the two groups were significantly difference 
(p<0.05). The blood glucose levels after treatment 
of the supplement increased by 28.9±6.6mg/dL 
compared to the placebo group in which the          
blood glucose level decreased by 7.8±5.5mg/dL 
(p<0.05) (Table III). Blood glucose level in 
supplement group increased may be caused by 
serving of supplement of soybean-based contain 
approximately 11g carbohydrate which could be 
metabolized into glucose. 
Soybean ingredient contain protein and 
isoflavon of genistein. Protein in gastrointestinal 
tract   were   brook   down  into amino acid.  Amino 
acid, glucose and genistein have an effect to 
stimulate secretion of GLP-1 that stimulate beta cell 
pancreas to release insulin. Therefore, after given 
soybean supplement in the supplement group 
insulin levels should increase and accordingly 
glucose levels decrease. However in this study the 
soybean suplement resulted in the increase of 
glucose levels (Tabel II). It could not be explained 
the logic of this phenomena. Administration of one 
serving of supplements made from soybeans 
containing 18 grams of protein can be given as a 
substitute for one meal without concurrent anti-
diabetic drugs if the basal glucose level is normal 
because the increase in blood glucose levels after 
administration is quite low with an average 
increase of 28.9±6.6mg/dL. 
The average postprandial glucose level of 
the supplement group was 351.0±19.8mg/dL 
compared with the placebo group of 
327.5±14.3mg/dL and this difference was not 
significant (p>0.05). Blood glucose levels after                
2h postprandial in the supplement group appeared 
to be higher than the placebo group because                  
at the beginning in the supplement group                  
showed higher glucose  level than in the  placebo                      
group (Table III). After 2h postprandial with 75g 
glucose loading and after soybean supplement 
treatment showed that in the supplement group 
there was an increase in blood glucose levels by 
130.0±11.5 mg/dL, this was comparable to the 
increase the glucose level in the placebo group, 
which the increase was 146.7±8.2 mg/dL (p>0.05).  
Table III. Increase in blood glucose levels after supplementation and 2h postprandial. 
 
Group 
Mean±SEM of Increase Blood Glucose Level (mg/dL) 
Supplement n=37 Placebo-H2O n=39 p-value 
Post Treatment (supplementation) 28.9±6.6 (7.8±5.5) <0.05 
2h postprandial 130.0±11.5 146.7±8.2 >0.05 
 
SEM: Standard Error Mean 
 
Tabel IV. Blood Insulin Level (μIU/mL) and  Blood Glucose Level (mg/dL). Subject treated with insulin 
excluded 
 
Group 
Blood Insulin Level (μU/mL Blood Glucose Level (mg/dL) 
Suplement group 
N=26 
Placebo 
N=24 
p-value 
Suplement group 
N=26 
Placebo 
N=24 
p-value 
Fasting 9.5±2.9 13.5±3.0 >0.05 212.3±15.8 182.3±13.8 >0.05 
Post Suplement 15.2±3.1 12.9±2.9 >0.05 237.3±18.8 170.8±11.0 <0.05 
2h postprandial    355.3±25.5 304.5±15.0 >0.05 
Increase 5.7±1.0 (0.6±0.5) <0.05    
 
Tabel V. Increased of Blood Glucose Level (mg/dL) after supplementation and 2h post prandial. Subject 
treated with insulin excluded 
 
Group Suplement group N=26 Placebo N=24 p-value 
Post Suplement 25.0±7.7 (10.8±7.5) <0.05 
2h post prandial 118.0±10.7 146.7±8.2.0 >0.05 
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 This results indicate that soybean 
supplementation have no effect in increasing blood 
glucose level for diabetic subjects. Most of blood 
glucose levels in the two groups were more than 
200mg/dL,   while   some  were below  200mg/dL. 
But the NNT (Number Needed to Treat) value 
between the supplement versus the placebo group 
was statistically not significant. Therefore, the use 
of soy-based supplements containing 18g of 
protein cannot be recommended as a specific 
therapy to control blood glucose levels in patients 
with T2DM. However, its use as a substitute for 
breakfast or dinner can still be suggested based on 
the average increase in glucose after the treatment 
of soy-based supplements, which was only 
28.9±6.6mg/dL. 
 
 
Figure 1. Gel electrophoresis PCR of DNA of GLP-1 gen 
 
 
 
Figure 2. the electropherogram of the result of 
capillary electrophoresis shows the normal 
sequence (wild type) of the gene of GLP-1 refers to 
coding region accession no NC_000002.12, the DNA 
sequence of antisense strand around Leu111 is  5’ 
GGCCTTCCAAATAAGAACTTACATCAC 3’ while the 
sense strand is 5’ 
GTGATGTAAGTTCTTATTTGGAAGGCC 3’. 
 
 
 
 
Figure 3. the electropherogram of the result of 
capillary electrophoresis shows the abnormal 
sequence of the gene of GLP-1, in the red box it 
visible to be lost one nucleotide (Adenine) 
compare to figure 1. In this electropherogram 
sequence of the antisense strand change to 5’ 
GGCCTTCC-AATAAGAACTTACATCAC 3’ while the 
sense strand still unchanged it same with the 
reference 5’ 
GTGATGTAAGTTCTTATTTGGAAGGCC 3’. 
 
 
Effect of Soybean-based Food Supplement 
214   Volume 30 Issue 3 (2019) 
 The changes of blood insulin and glucose 
level in the subject who do not use insulin during 
routine therapy (Table IV and V). It can be seen that 
the changes of the both parameter after 
supplementation and or after 2h-meal (2pp) 
exhibited similarity with the changes of those in all 
subjects involved, both subject with and without 
insulin during DM therapy. The result of DNA 
isolation of GLP-1 gene which amplified by PCR 
shows an image of amplification of DNA of GLP-1 
(37 amino acid) gene as band of 137 bp length of 
PCR product on gel electrophoresis (Figure 1). 
The sequencing results of the gene of GLP-1 
(37 amino acid) showed a difference of nucleotide 
sequences in the antisense strand than a normal 
reference which is CAA>C-A found in a most subject 
which coincided with the 111th amino acid of 
glucagon preproprotein, leucine (Leu111).                       
The Leu111 mRNA coding which is the sense strand 
is TTG. The normal double-stranded DNA 
according to accession number NC_000002.12 
precisely around the Leu111 of glucagon 
preproprotein (Figure 2).  
In this study, it was found that GLP-1 (37 
amino acid) sequencing examination showed 
abnormalities, antisense strand DNA sequences 
that coincided with the 111th amino acid of glucagon 
preproprotein precisely at the chromosome 
position NC_000002.12:g.162145600delA. Normal 
reference sequence of antisense strands nucleotide 
number 162145599-162145601 is 5’CAA3’ but the 
results of the examination found the subjects 
shows 5’C-A3’ sequences (Figure 3).  
There has never been reported a single 
nucleotide variation (SNV) of deletion (CAA>C-A) 
at the position of the amino acid Leu111 from             
the glucagon preproprotein gene. The NCBI 
Reference shows that the nucleotide variation 
associated with the Leu111 amino acid that exists 
is   substitution   on    antisense    strand   CAA>CAG  
 
which it sense strand TTG>CTG, it SNV is 
synonymous encoding leucine amino acids and its 
occurrence is very rare with minor allele frequency 
(MAF) less than 0.0001. Deletion at the position 
NC_000002.12:g.162145600delA in diabetics 
patients of the Javanese  may relate to the changes 
of insulin levels need require more extensive and 
more rigorous study, so far, these single nucleotide 
variations have not been reported at all. However, 
if indeed the deletion exists even though it has not 
been disturbed clinically so the absence of 
nucleotides on one side of the DNA strand will 
make an unstable DNA. This condition allows            
other nucleotides to be occupied or a pair of 
nucleotides will disappear and affect the                 
protein product when DNA transcribed and then 
translated in the process of protein synthesis. 
Finally, the amino acid composition of protein 
products may change and may affect its                  
function clinical manifest as a disorder or disease.                    
Theoretically adenine deletion on antisense            
strand position NC_000002.12:g.162145600delA                                    
may change amino acid sequence 
(DVSSYlegqaakefiawlvk...(+55 amino acids)...*-
>DVSSYwkaklprnsllgw*) so it will influent the GLP-
1 function. In this study, the administration of 
supplement change insulin level (2=0.40 p<0.05), 
the changes may/may not relate to genetic 
variation. The increase in blood insulin levels              
after the soybean supplement treatment appeared 
to be higher in the normal genotype group of 
7.1±2.9µIU/mL (n=6) compared to the abnormal 
(mutant) genotype group of 4.9±0.7µIU/mL  
(n=29) the correlation 2=0.41 statistically 
significance (p<0.05). More clearly with respect          
to subjects with normal and abnormal DNA 
sequences to insulin levels and blood glucose levels 
both in the treatment group of soybean 
supplements and the control group can be 
observed (tables VI). 
 
Table VI. Difference in blood insulin levels and blood glucose levels in soy supplementation based on   GPL-
1 genetic variations of antisense strand NC_000002.12: g.162145600delA. 
 
Group 
Average ±SEM difference blood insulin 
level  (μU/mL) 
 Average ±SEM difference blood 
Glucose Level (mg/dL) 
Suplement  Placebo p-value Suplement  Placebo p-value 
AA (n) 7.2±2.9 (6) 1.1±0.9 (10) <0.05 133.6±36.5 (6) 153.4±18.7 >0.05 
DelA (n) 4.9±0.8 (31) (-0.9±0.5) 
(27) 
<0.05 129.4±12.2 (31) 143.5±9.7 
(27) 
>0.05 
 
SEM: Standard Error Mean blood insulin level, ƞ2=0.41 p<0.05, Mean blood glucose level, ƞ2=0.02 p>0.05, 
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CONCLUSION 
From the study, it can be concluded that 
there is a relationship between the administration 
of soybean supplements and the changes of blood 
glucose and insulin levels. Genetic variation in 
normal genotypes of GLP-1 at the position of the 
antisense strand NC_000002.12: g.162145600delA 
may relate to the cganges blood insulin levels. The 
administration of soy-based supplements 
containing 18g of protein increased blood insulin 
levels and suppressed blood glucose levels but 
cannot reversed back to normal levels. Although it 
cannot be used as specific therapy in Type 2 
diabetes mellitus, one serving supplement as a 
substitute for a meal can be recommended without 
anti-diabetic medications if the basal glucose level 
is normal. 
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